WebNeoadjuvant Treatment of Breast Cancer Administer PHESGO every 3 weeks for 3 to 6 cycles as part of a treatment regimen for early breast cancer [see Clinical Studies (14.2)]. Refer to the prescribing information for pertuzumab, administered in combination with trastuzumab and chemotherapy, for recommended dose and dosage modifications. WebOct 13, 2024 · What is Phesgo and how is it used? Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a combination of HER2/neu receptor antagonists and an endoglycosidase indicated for use in combination with chemotherapy as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage …

FDA Approves Phesgo as Injection Treatment for ... - Breast …

WebCancer is a disease caused by changes, also known as mutations, in DNA that change the way cells grow and divide. ... Previously, trastuzumab and pertuzumab were used … WebPhesgo® belongs to a group of cancer drugs called monoclonal antibodies. Monoclonal antibodies are sometimes called targeted therapies because they work by ‘targeting’ specific proteins (receptors) on the surface of cells. Phesgo® locks onto the HER2 protein. This blocks the receptor and stops the cells from dividing and growing. dashi is a basic stock made from seaweed and

Pertuzumab, Trastuzumab, and Hyaluronidase (Phesgo)

WebPHESGO TM is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic test. Important Safety Information WebPhesgo is a combination medication containing pertuzumab, trastuzumab, and hyaluronidase or hyaluronidase-zzxf. It's a targeted anticancer treatment for HER2-positive breast cancer that’s either in the early or metastatic stage. Phesgo is an injection that’s given under the skin, and it’s typically used along with other chemotherapy. WebBrief Summary: This Phase III, randomized, two-arm, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus Phesgo compared with Phesgo after induction therapy with Phesgo plus taxane in participants with human epidermal growth factor receptor 2 (HER2)-positive, estrogen receptor (ER)-positive advanced breast cancer … bite beauty stick swatches